Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...

Gilead Sciences’ shares closed up 2.7% at $83.16 yesterday, after it releases positive results of an interim analysis from a ...

An injected antiviral medicine, taken twice a year, appears to offer at-risk people near-complete protection against HIV ...

If approved, lenacapavir would be the first and only twice-yearly HIV prevention choice for people who need or want PrEP.

A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis ...

Patients with HIV treated with antiretroviral therapy (ART) have a 31.5% chance of being anemic with many significantly ...

Long-term daily oral pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide was safe and highly effective for HIV prevention in adult cisgender men and transgender women who have sex ...

aDivision of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California, San Francisco (UCSF), 995 Potrero Avenue, Building 80, 4th floor, San Francisco, CA 94110, ...

Lupin also has received tentative approval from the Food and Drug Administration under the U.S. President’s Emergency Plan for AIDS Relief for Emtricitabine and Tenofovir Alafenamide Tablets ...